USPTO serial 77937687
ARK THERAPEUTICS
Reviewed by CopyMark Law Group
Reg. 4184675Status 710
- Filing date
- Status date
- Registration date
- Aug 7, 2012
- Examiner
- LE, KHANH M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with ARK THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
London, W1W 6XB, GB
London, W1W 6XB, GB
London, W1W 6XB, GB
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic protein preparations for use in science, scientific diagnostics, medical laboratory use and research; diagnostic preparations of genes for use in science, scientific diagnostics, medical laboratory use and research | SECTION 8 - CANCELLED | — |
| 005 | Diagnostic protein preparations for medical use; diagnostic preparations of genes for medical use; pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely, for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutic purposes, namely, for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes, namely, for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes, namely, to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes, namely, for increasing the efficiency of muscle cell energy production; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; none of the above including dietary and nutritional supplements | SECTION 8 - CANCELLED | — |
| 010 | Boots and gloves for orthopaedic and medical purposes; parts of boots and gloves for orthopedic and medical purposes, namely, heels, soles and inserts; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for boots and gloves for medical purposes, namely, for the treatment of wounds and burns; biodegradable collagen collar delivery devices for delivering therapeutic agents and gene therapy products to specific sites | SECTION 8 - CANCELLED | — |
| 042 | Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; providing scientific, medical and clinical research information, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; none of the above in the dietary or nutritional supplement field | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Ark Therapeutics Limited
- Other trademarks owned by Ark Therapeutics Limited
- Other trademarks owned by Ark Therapeutics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named ARK THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 8, 2019 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Aug 7, 2017 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 7, 2012 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 28, 2012 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Jun 28, 2012 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jun 28, 2012 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 22, 2012 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| May 29, 2012 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 3, 2012 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 3, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 14, 2012 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 27, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 21, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 10, 2012 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 10, 2012 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 10, 2012 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 10, 2012 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 1, 2012 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 1, 2012 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 10, 2012 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 12, 2011 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 12, 2011 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 12, 2011 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 21, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 21, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 15, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 21, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 30, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 30, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 29, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 27, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 9, 2010 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Apr 8, 2010 | ALIE | ASSIGNED TO LIE | — |
| Mar 29, 2010 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 23, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 20, 2010 | NWAP | NEW APPLICATION ENTERED | — |